Current status and prospects of gemcitabine resistance in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma(PDAC)is a highly aggressive malignant tumor of the digestive system.The morbidity and mortality rates are on the rise year by year,and the five-year survival rate of patients is less than 10％.Despite the current recognition of surgical resection as the only potentially curative treatment for PDAC,the majority of patients are diagnosed at an advanced stage,missing the best opportunity for surgical intervention.Gemcitabine,a first-line chemotherapy drug for PDAC,has been widely used in clinical practice,but the emerging issue of drug resistance severely limits its therapeutic ef-ficacy and the improvement of patients'prognoses.In this article,we systematically reviewed and analyzed the molecular mechanism of gemcitabine resistance in PDAC combined with the research findings of our team,and on the basis of which,we thoroughly explored multiple strategies for reversing gemcitabine resist-ance in PDAC.This study not only provides a new theoretical perspective for the comprehensive treatment of PDAC,but also reveals a number of therapeutic targets with clinical application prospects,which is ex-pected to open up novel options for the treatment of PDAC.
NETL
NSTL
万方数据
